Nivolumab
Kidney Neoplasm
Bristol-Myers Squibbmonoclonal_antibodyPhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
17 Active assets in the Kidney Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib Pfizer | Phase 3 | BB |
Ipilimumab Pfizer | Phase 4 | BB |
Adriamycin Merck Sharp & Dohme LLC | Phase 2 | BB |
Sorafenib Pfizer | Phase 3 | B |
Temsirolimus Pfizer | Phase 3 | B |
View all 49 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →